{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:16:17Z","timestamp":1792696577636,"version":"4.5.0"},"reference-count":225,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40120-025-00793-z","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T06:04:49Z","timestamp":1752818689000},"page":"1747-1767","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Neuroprotection in Parkinson Disease"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6809-0127","authenticated-orcid":false,"given":"Cristina","family":"Gonzalez-Robles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3149-0252","authenticated-orcid":false,"given":"Oliver","family":"Bandmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3018-3966","authenticated-orcid":false,"given":"Anthony H. V.","family":"Schapira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"issue":"9996","key":"793_CR1","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson\u2019s disease. Lancet. 2015;386(9996):896\u2013912.","journal-title":"Lancet"},{"issue":"2","key":"793_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1176\/jnp.14.2.223","volume":"14","author":"J Parkinson","year":"2002","unstructured":"Parkinson J. An essay on the shaking palsy. J Neuropsychiatry Clin Neurosci. 2002;14(2):223\u201336.","journal-title":"J Neuropsychiatry Clin Neurosci."},{"issue":"7310","key":"793_CR3","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1038\/466S6a","volume":"466","author":"A Abbott","year":"2010","unstructured":"Abbott A. Levodopa: the story so far. Nature. 2010;466(7310):S6-7.","journal-title":"Nature."},{"issue":"9","key":"793_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.863921","volume":"23","author":"SN Serva","year":"2022","unstructured":"Serva SN, Bernstein J, Thompson JA, Kern DS, Ojemann SG. An update on advanced therapies for Parkinson\u2019s disease: from gene therapy to neuromodulation. Front Surg. 2022;23(9): 863921.","journal-title":"Front Surg"},{"issue":"7","key":"793_CR5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","volume":"20","author":"N Vijiaratnam","year":"2021","unstructured":"Vijiaratnam N, Simuni T, Bandmann O, Morris HR, Foltynie T. Progress towards therapies for disease modification in Parkinson\u2019s disease. Lancet Neurol. 2021;20(7):559\u201372.","journal-title":"Lancet Neurol"},{"issue":"5","key":"793_CR6","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3233\/JPD-240272","volume":"14","author":"K McFarthing","year":"2024","unstructured":"McFarthing K, Buff S, Rafaloff G, Pitzer K, Fiske B, Navangul A, et al. Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2024 update. J Parkinson\u2019s Dis. 2024;14(5):899\u2013912.","journal-title":"J Parkinson\u2019s Dis"},{"issue":"12","key":"793_CR7","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41582-024-01023-0","volume":"20","author":"LV Kalia","year":"2024","unstructured":"Kalia LV, Asis A, Arbour N, Bar-Or A, Bove R, Di Luca DG, et al. Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis. Nat Rev Neurol. 2024;20(12):724\u201337.","journal-title":"Nat Rev Neurol"},{"key":"793_CR8","doi-asserted-by":"crossref","unstructured":"Barker RA, Bj\u00f6rklund A. Restorative cell and gene therapies for Parkinson\u2019s disease. In: Handbook of clinical neurology [Internet]. Elsevier; 2023. p. 211\u201326. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780323855556000126. Accessed 28 Jan 2025.","DOI":"10.1016\/B978-0-323-85555-6.00012-6"},{"issue":"10","key":"793_CR9","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1007\/s10072-024-07599-1","volume":"45","author":"J Grote","year":"2024","unstructured":"Grote J, Patel N, Bates C, Parmar MS. From lab bench to hope: a review of gene therapies in clinical trials for Parkinson\u2019s disease and challenges. Neurol Sci. 2024;45(10):4699\u2013710.","journal-title":"Neurol Sci"},{"issue":"6","key":"793_CR10","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1474-4422(16)00060-0","volume":"15","author":"D Salat","year":"2016","unstructured":"Salat D, Noyce AJ, Schrag A, Tolosa E. Challenges of modifying disease progression in prediagnostic Parkinson\u2019s disease. Lancet Neurol. 2016;15(6):637\u201348.","journal-title":"Lancet Neurol"},{"issue":"7_Supplement_1","key":"793_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1212\/WNL.0000000000200787","volume":"99","author":"JM Janssen Daalen","year":"2022","unstructured":"Janssen Daalen JM, Schootemeijer S, Richard E, Darweesh SKL, Bloem BR. Lifestyle interventions for the prevention of parkinson disease: a recipe for action. Neurology. 2022;99(7_Supplement_1):42\u201351.","journal-title":"Neurology"},{"issue":"7_Supplement_1","key":"793_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1212\/WNL.0000000000200238","volume":"99","author":"GF Crotty","year":"2022","unstructured":"Crotty GF, Schwarzschild MA. What to test in parkinson disease prevention trials? Repurposed, low-risk, and gene-targeted drugs. Neurology. 2022;99(7_Supplement_1):34\u201341.","journal-title":"Neurology"},{"issue":"s2","key":"793_CR13","doi-asserted-by":"publisher","first-page":"S381","DOI":"10.3233\/JPD-240164","volume":"14","author":"GF Crotty","year":"2024","unstructured":"Crotty GF, Ayer SJ, Schwarzschild MA. Designing the first trials for Parkinson\u2019s prevention. Berg D, Bloem BR, Kalia LV, Postuma RB, editors. J Parkinson\u2019s Dis. 2024;14(s2):S381\u201393.","journal-title":"J Parkinson\u2019s Dis."},{"issue":"10416","key":"793_CR14","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","volume":"402","author":"A Di Matteo","year":"2023","unstructured":"Di Matteo A, Bathon JM, Emery P. Rheumatoid arthritis. Lancet. 2023;402(10416):2019\u201333.","journal-title":"Lancet"},{"issue":"10","key":"793_CR15","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1080\/17512433.2024.2410393","volume":"17","author":"G Dalla Costa","year":"2024","unstructured":"Dalla Costa G, Leocani L, Rodegher M, Chiveri L, Gradassi A, Comi G. An overview on disease modifying and symptomatic drug treatments for multiple sclerosis. Expert Rev Clin Pharmacol. 2024;17(10):901\u201321.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"793_CR16","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s41596-022-00787-3","volume":"18","author":"L Concha-Marambio","year":"2023","unstructured":"Concha-Marambio L, Pritzkow S, Shahnawaz M, Farris CM, Soto C. Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid. Nat Protoc. 2023;18(4):1179\u201396.","journal-title":"Nat Protoc"},{"issue":"6","key":"793_CR17","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","volume":"29","author":"A Okuzumi","year":"2023","unstructured":"Okuzumi A, Hatano T, Matsumoto G, Nojiri S, Ueno S, Imamichi-Tatano Y, et al. Propagative \u03b1-synuclein seeds as serum biomarkers for synucleinopathies. Nat Med. 2023;29(6):1448\u201355.","journal-title":"Nat Med"},{"issue":"5","key":"793_CR18","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf A, Concha-Marambio L, Lafontant DE, Farris CM, Ma Y, Urenia PA, et al. Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 2023;22(5):407\u201317.","journal-title":"Lancet Neurol"},{"issue":"2","key":"793_CR19","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, et al. A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024;23(2):178\u201390.","journal-title":"Lancet Neurol"},{"issue":"2","key":"793_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger GU, Adler CH, Berg D, Klein C, Outeiro TF, Poewe W, et al. A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 2024;23(2):191\u2013204.","journal-title":"Lancet Neurol"},{"issue":"10","key":"793_CR21","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00702-024-02797-9","volume":"131","author":"GU H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger GU, Lang AE. The why and how of the SynNerGe criteria of Parkinson\u2019s disease. J Neural Transm. 2024;131(10):1149\u201354.","journal-title":"J Neural Transm"},{"issue":"7179","key":"793_CR22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/bmj.318.7179.311","volume":"318","author":"AHV Schapira","year":"1999","unstructured":"Schapira AHV. Science, medicine, and the future: Parkinson\u2019s disease. BMJ. 1999;318(7179):311\u20134.","journal-title":"BMJ"},{"key":"793_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.expneurol.2017.10.002","volume":"298","author":"J Blesa","year":"2017","unstructured":"Blesa J, Trigo-Damas I, Dileone M, Del Rey NLG, Hernandez LF, Obeso JA. Compensatory mechanisms in Parkinson\u2019s disease: circuits adaptations and role in disease modification. Exp Neurol. 2017;298:148\u201361.","journal-title":"Exp Neurol"},{"issue":"5","key":"793_CR24","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/mds.27360","volume":"33","author":"AE Lang","year":"2018","unstructured":"Lang AE, Espay AJ. Disease modification in Parkinson\u2019s disease: current approaches, challenges, and future considerations. Mov Disord. 2018;33(5):660\u201377.","journal-title":"Mov Disord"},{"issue":"5","key":"793_CR25","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00702-002-0808-2","volume":"110","author":"H Braak","year":"2003","unstructured":"Braak H, R\u00fcb U, Gai WP, Del Tredici K. Idiopathic Parkinson\u2019s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. 2003;110(5):517\u201336.","journal-title":"J Neural Transm"},{"issue":"2","key":"793_CR26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Tredici KD, R\u00fcb U, De Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging. 2003;24(2):197\u2013211.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"793_CR27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.neulet.2005.11.012","volume":"396","author":"H Braak","year":"2006","unstructured":"Braak H, De Vos RAI, Bohl J, Del Tredici K. Gastric \u03b1-synuclein immunoreactive inclusions in Meissner\u2019s and Auerbach\u2019s plexuses in cases staged for Parkinson\u2019s disease-related brain pathology. Neurosci Lett. 2006;396(1):67\u201372.","journal-title":"Neurosci Lett"},{"issue":"6","key":"793_CR28","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1365-2990.2007.00874.x","volume":"33","author":"CH Hawkes","year":"2007","unstructured":"Hawkes CH, Del Tredici K, Braak H. Parkinson\u2019s disease: a dual-hit hypothesis. Neuropathol Appl Neurobio. 2007;33(6):599\u2013614.","journal-title":"Neuropathol Appl Neurobio"},{"issue":"s2","key":"793_CR29","doi-asserted-by":"publisher","first-page":"S281","DOI":"10.3233\/JPD-191721","volume":"9","author":"P Borghammer","year":"2019","unstructured":"Borghammer P, Van Den Berge N. Brain-first versus gut-first Parkinson\u2019s disease: a hypothesis. Van Laar T, editor. J Parkinson\u2019s Dis. 2019;9(s2):S281\u201395.","journal-title":"J Parkinson\u2019s Dis"},{"issue":"6","key":"793_CR30","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00702-023-02633-6","volume":"130","author":"P Borghammer","year":"2023","unstructured":"Borghammer P. The brain-first vs. body-first model of Parkinson\u2019s disease with comparison to alternative models. J Neural Transm. 2023;130(6):737\u201353.","journal-title":"J Neural Transm"},{"issue":"2","key":"793_CR31","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S1474-4422(19)30356-4","volume":"19","author":"JF Cryan","year":"2020","unstructured":"Cryan JF, O\u2019Riordan KJ, Sandhu K, Peterson V, Dinan TG. The gut microbiome in neurological disorders. Lancet Neurol. 2020;19(2):179\u201394.","journal-title":"Lancet Neurol"},{"issue":"1","key":"793_CR32","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/07853890.2021.1890330","volume":"53","author":"E Menozzi","year":"2021","unstructured":"Menozzi E, Macnaughtan J, Schapira AHV. The gut-brain axis and Parkinson disease: clinical and pathogenetic relevance. Ann Med. 2021;53(1):611\u201325.","journal-title":"Ann Med"},{"issue":"4","key":"793_CR33","doi-asserted-by":"publisher","first-page":"NS20210026","DOI":"10.1042\/NS20210026","volume":"5","author":"J Lama","year":"2021","unstructured":"Lama J, Buhidma Y, Fletcher EJR, Duty S. Animal models of Parkinson\u2019s disease: a guide to selecting the optimal model for your research. Neuronal Signal. 2021;5(4):NS20210026.","journal-title":"Neuronal Signal."},{"issue":"1","key":"793_CR34","doi-asserted-by":"publisher","first-page":"223","DOI":"10.14336\/AD.2020.0331","volume":"12","author":"M Ke","year":"2021","unstructured":"Ke M, Chong CM, Zhu Q, Zhang K, Cai CZ, Lu JH, et al. Comprehensive perspectives on experimental models for Parkinson\u2019s disease. Aging Dis. 2021;12(1):223.","journal-title":"Aging Dis"},{"issue":"1","key":"793_CR35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40035-023-00368-8","volume":"12","author":"A Dovonou","year":"2023","unstructured":"Dovonou A, Bolduc C, Soto Linan V, Gora C, Peralta Iii MR, L\u00e9vesque M. Animal models of Parkinson\u2019s disease: bridging the gap between disease hallmarks and research questions. Transl Neurodegener. 2023;12(1):36.","journal-title":"Transl Neurodegener"},{"key":"793_CR36","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1056\/NEJM198911163212004","volume":"321","author":"The Parkinson Study Group","year":"1989","unstructured":"The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson\u2019s disease. N Engl J Med. 1989;321:1364\u201371.","journal-title":"N Engl J Med"},{"issue":"3","key":"793_CR37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/pst.355","volume":"8","author":"BA Ploeger","year":"2009","unstructured":"Ploeger BA, Holford NHG. Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis. Pharm Stat. 2009;8(3):225\u201338.","journal-title":"Pharm Stat"},{"issue":"13","key":"793_CR38","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1056\/NEJMsm0904209","volume":"361","author":"RB D\u2019Agostino","year":"2009","unstructured":"D\u2019Agostino RB. The delayed-start study design. N Engl J Med. 2009;361(13):1304\u20136.","journal-title":"N Engl J Med"},{"issue":"5","key":"793_CR39","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1474-4422(11)70073-4","volume":"10","author":"O Rascol","year":"2011","unstructured":"Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, et al. A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011;10(5):415\u201323.","journal-title":"Lancet Neurol"},{"issue":"1","key":"793_CR40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13195-022-01015-6","volume":"14","author":"J Cummings","year":"2022","unstructured":"Cummings J, Montes A, Kamboj S, Cacho JF. The role of basket trials in drug development for neurodegenerative disorders. Alzheimer\u2019s Res Ther. 2022;14(1):73.","journal-title":"Alzheimer's Res Ther"},{"issue":"7","key":"793_CR41","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1093\/brain\/awad063","volume":"146","author":"T Foltynie","year":"2023","unstructured":"Foltynie T, Gandhi S, Gonzalez-Robles C, Zeissler ML, Mills G, Barker R, et al. Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson\u2019s disease. Brain. 2023;146(7):2717\u201322.","journal-title":"Brain"},{"issue":"18","key":"793_CR42","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0000000000200604","volume":"98","author":"V Li","year":"2022","unstructured":"Li V, Leurent B, Barkhof F, Braisher M, Cafferty F, Ciccarelli O, et al. Designing multi-arm multistage adaptive trials for neuroprotection in progressive multiple sclerosis. Neurology. 2022;98(18):754\u201364.","journal-title":"Neurology"},{"issue":"7","key":"793_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-064173","volume":"12","author":"C Wong","year":"2022","unstructured":"Wong C, Dakin RS, Williamson J, Newton J, Steven M, Colville S, et al. Motor neuron disease systematic multi-arm adaptive randomised trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease. BMJ Open. 2022;12(7): e064173.","journal-title":"BMJ Open"},{"issue":"3","key":"793_CR44","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/mds.26913","volume":"32","author":"AJ Espay","year":"2017","unstructured":"Espay AJ, Schwarzschild MA, Tanner CM, Fernandez HH, Simon DK, Leverenz JB, et al. Biomarker-driven phenotyping in Parkinson\u2019s disease: a translational missing link in disease-modifying clinical trials. Mov Disord. 2017;32(3):319\u201324.","journal-title":"Mov Disord"},{"issue":"4","key":"793_CR45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11910-017-0738-x","volume":"17","author":"SM Fereshtehnejad","year":"2017","unstructured":"Fereshtehnejad SM, Postuma RB. Subtypes of Parkinson\u2019s disease: what do they tell us about disease progression? Curr Neurol Neurosci Rep. 2017;17(4):34.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"793_CR46","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3233\/JPD-212818","volume":"12","author":"K Brolin","year":"2022","unstructured":"Brolin K, Bandres-Ciga S, Blauwendraat C, Widner H, Odin P, Hansson O, et al. Insights on genetic and environmental factors in Parkinson\u2019s disease from a regional swedish case\u2013control cohort. JPD. 2022;12(1):153\u201371.","journal-title":"JPD"},{"key":"793_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105935","volume":"119","author":"J Dulski","year":"2024","unstructured":"Dulski J, Uitti RJ, Beasley A, Hernandez D, Ramanan VK, Cahn EJ, et al. Genetics of Parkinson\u2019s disease heterogeneity: a genome-wide association study of clinical subtypes. Parkinsonism Relat Disord. 2024;119: 105935.","journal-title":"Parkinsonism Relat Disord"},{"key":"793_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2020.101772","volume":"187","author":"PJ Carling","year":"2020","unstructured":"Carling PJ, Mortiboys H, Green C, Mihaylov S, Sandor C, Schwartzentruber A, et al. Deep phenotyping of peripheral tissue facilitates mechanistic disease stratification in sporadic Parkinson\u2019s disease. Prog Neurobiol. 2020;187: 101772.","journal-title":"Prog Neurobiol"},{"issue":"8","key":"793_CR49","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s42256-023-00702-9","volume":"5","author":"K D\u2019Sa","year":"2023","unstructured":"D\u2019Sa K, Evans JR, Virdi GS, Vecchi G, Adam A, Bertolli O, et al. Prediction of mechanistic subtypes of Parkinson\u2019s using patient-derived stem cell models. Nat Mach Intell. 2023;5(8):933\u201346.","journal-title":"Nat Mach Intell"},{"issue":"6","key":"793_CR50","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3233\/JPD-230051","volume":"13","author":"C Gonzalez-Robles","year":"2023","unstructured":"Gonzalez-Robles C, Weil RS, Van Wamelen D, Bartlett M, Burnell M, Clarke CS, et al. Outcome measures for disease-modifying trials in Parkinson\u2019s disease: consensus paper by the EJS ACT-PD multi-arm multi-stage trial initiative. JPD. 2023;13(6):1011\u201333.","journal-title":"JPD"},{"issue":"4","key":"793_CR51","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11910-024-01335-0","volume":"24","author":"D Bendetowicz","year":"2024","unstructured":"Bendetowicz D, Fabbri M, Sirna F, Fernagut PO, Foubert-Samier A, Saulnier T, et al. Recent advances in clinical trials in multiple system atrophy. Curr Neurol Neurosci Rep. 2024;24(4):95\u2013112.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"12","key":"793_CR52","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/S1474-4422(24)00396-X","volume":"23","author":"F Krismer","year":"2024","unstructured":"Krismer F, Fanciulli A, Meissner WG, Coon EA, Wenning GK. Multiple system atrophy: advances in pathophysiology, diagnosis, and treatment. Lancet Neurol. 2024;23(12):1252\u201366.","journal-title":"Lancet Neurol"},{"issue":"4","key":"793_CR53","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/med.21257","volume":"32","author":"S Magesh","year":"2012","unstructured":"Magesh S, Chen Y, Hu L. Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med Res Rev. 2012;32(4):687\u2013726.","journal-title":"Med Res Rev"},{"key":"793_CR54","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fphys.2020.00064","volume":"11","author":"WA Al-Megrin","year":"2020","unstructured":"Al-Megrin WA, Soliman D, Kassab RB, Metwally DM, Moneim AEA, El-Khadragy MF. Coenzyme Q10 activates the antioxidant machinery and inhibits the inflammatory and apoptotic cascades against lead acetate-induced renal injury in rats. Front Physiol. 2020;11:64.","journal-title":"Front Physiol"},{"issue":"7","key":"793_CR55","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1007\/s11011-021-00795-4","volume":"36","author":"E Ghasemloo","year":"2021","unstructured":"Ghasemloo E, Mostafavi H, Hosseini M, Forouzandeh M, Eskandari M, Mousavi SS. Neuroprotective effects of coenzyme Q10 in Parkinson\u2019s model via a novel Q10\/miR-149-5p\/MMPs pathway. Metab Brain Dis. 2021;36(7):2089\u2013100.","journal-title":"Metab Brain Dis"},{"issue":"6","key":"793_CR56","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3390\/jpm12060975","volume":"12","author":"FJ Jim\u00e9nez-Jim\u00e9nez","year":"2022","unstructured":"Jim\u00e9nez-Jim\u00e9nez FJ, Alonso-Navarro H, Garc\u00eda-Mart\u00edn E, Ag\u00fandez JAG. Coenzyme Q10 and Parkinsonian syndromes: a systematic review. JPM. 2022;12(6):975.","journal-title":"JPM"},{"issue":"1","key":"793_CR57","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2174\/1871527314666150821103306","volume":"15","author":"A Negida","year":"2016","unstructured":"Negida A, Menshawy A, El Ashal G, Elfouly Y, Hani Y, Hegazy Y, et al. Coenzyme Q10 for patients with Parkinson\u2019s disease: a systematic review and meta-analysis. CNSNDDT. 2016;15(1):45\u201353.","journal-title":"CNSNDDT"},{"issue":"2","key":"793_CR58","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10072-016-2757-9","volume":"38","author":"ZG Zhu","year":"2017","unstructured":"Zhu ZG, Sun MX, Zhang WL, Wang WW, Jin YM, Xie CL. The efficacy and safety of coenzyme Q10 in Parkinson\u2019s disease: a meta-analysis of randomized controlled trials. Neurol Sci. 2017;38(2):215\u201324.","journal-title":"Neurol Sci"},{"issue":"1","key":"793_CR59","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s42466-019-0033-1","volume":"1","author":"J Prasuhn","year":"2019","unstructured":"Prasuhn J, Br\u00fcggemann N, Hessler N, Berg D, Gasser T, Brockmann K, et al. An omics-based strategy using coenzyme Q10 in patients with Parkinson\u2019s disease: concept evaluation in a double-blind randomized placebo-controlled parallel group trial. Neurol Res Pract. 2019;1(1):31.","journal-title":"Neurol Res Pract"},{"issue":"11","key":"793_CR60","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.freeradbiomed.2010.08.028","volume":"49","author":"A Ghosh","year":"2010","unstructured":"Ghosh A, Chandran K, Kalivendi SV, Joseph J, Antholine WE, Hillard CJ, et al. Neuroprotection by a mitochondria-targeted drug in a Parkinson\u2019s disease model. Free Radic Biol Med. 2010;49(11):1674\u201384.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"793_CR61","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.bbadis.2012.07.009","volume":"1832","author":"ME Solesio","year":"2013","unstructured":"Solesio ME, Prime TA, Logan A, Murphy MP, Del Mar Arroyo-Jimenez M, Jord\u00e1n J, et al. The mitochondria-targeted anti-oxidant MitoQ reduces aspects of mitochondrial fission in the 6-OHDA cell model of Parkinson\u2019s disease. Biochim Biophys Acta (BBA) Mol Basis Dis. 2013;1832(1):174\u201382.","journal-title":"Biochim Biophys Acta (BBA) Mol Basis Dis."},{"issue":"11","key":"793_CR62","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1002\/mds.23148","volume":"25","author":"BJ Snow","year":"2010","unstructured":"Snow BJ, Rolfe FL, Lockhart MM, Frampton CM, O\u2019Sullivan JD, Fung V, et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson\u2019s disease. Mov Disord. 2010;25(11):1670\u20134.","journal-title":"Mov Disord"},{"issue":"2","key":"793_CR63","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/nano8020087","volume":"8","author":"L Montenegro","year":"2018","unstructured":"Montenegro L, Turnaturi R, Parenti C, Pasquinucci L. Idebenone: novel strategies to improve its systemic and local efficacy. Nanomaterials. 2018;8(2):87.","journal-title":"Nanomaterials"},{"issue":"3","key":"793_CR64","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s11064-020-03186-w","volume":"46","author":"B Avc\u0131","year":"2021","unstructured":"Avc\u0131 B, G\u00fcnayd\u0131n C, G\u00fcven\u00e7 T, Yavuz CK, Kuruca N, Bilge SS. Idebenone ameliorates rotenone-induced Parkinson\u2019s disease in rats through decreasing lipid peroxidation. Neurochem Res. 2021;46(3):513\u201322.","journal-title":"Neurochem Res"},{"issue":"1","key":"793_CR65","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41420-022-00826-8","volume":"8","author":"J Yan","year":"2022","unstructured":"Yan J, Sun W, Shen M, Zhang Y, Jiang M, Liu A, et al. Idebenone improves motor dysfunction, learning and memory by regulating mitophagy in MPTP-treated mice. Cell Death Discov. 2022;8(1):28.","journal-title":"Cell Death Discov"},{"issue":"5","key":"793_CR66","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/mus.1055","volume":"24","author":"MA Tarnopolsky","year":"2001","unstructured":"Tarnopolsky MA, Parshad A, Walzel B, Schlattner U, Wallimann T. Creatine transporter and mitochondrial creatine kinase protein content in myopathies. Muscle Nerve. 2001;24(5):682\u20138.","journal-title":"Muscle Nerve"},{"issue":"1","key":"793_CR67","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1006\/exnr.1999.7049","volume":"157","author":"RT Matthews","year":"1999","unstructured":"Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol. 1999;157(1):142\u20139.","journal-title":"Exp Neurol"},{"issue":"5","key":"793_CR68","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1212\/01.wnl.0000201252.57661.e1","volume":"66","author":"The NINDS NET-PD Investigators","year":"2006","unstructured":"The NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006;66(5):664\u201371.","journal-title":"Neurology"},{"issue":"1","key":"793_CR69","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1212\/01.wnl.0000250355.28474.8e","volume":"68","author":"The NINDS NET-PD Investigators","year":"2007","unstructured":"The NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007;68(1):20\u20138.","journal-title":"Neurology"},{"issue":"3","key":"793_CR70","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/WNF.0b013e3181342f32","volume":"31","author":"NINDS NET-PD Investigators","year":"2008","unstructured":"NINDS NET-PD Investigators. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol. 2008;31(3):141\u201350.","journal-title":"Clin Neuropharmacol."},{"issue":"6","key":"793_CR71","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1001\/jama.2015.120","volume":"313","author":"K Kieburtz","year":"2015","unstructured":"Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015;313(6):584.","journal-title":"JAMA"},{"issue":"10","key":"793_CR72","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1016\/j.celrep.2018.05.009","volume":"23","author":"DC Sch\u00f6ndorf","year":"2018","unstructured":"Sch\u00f6ndorf DC, Ivanyuk D, Baden P, Sanchez-Martinez A, De Cicco S, Yu C, et al. The NAD+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in iPSC and fly models of Parkinson\u2019s disease. Cell Rep. 2018;23(10):2976\u201388.","journal-title":"Cell Rep"},{"issue":"3","key":"793_CR73","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.cmet.2022.02.001","volume":"34","author":"B Brakedal","year":"2022","unstructured":"Brakedal B, D\u00f6lle C, Riemer F, Ma Y, Nido GS, Skeie GO, et al. The NADPARK study: a randomized phase I trial of nicotinamide riboside supplementation in Parkinson\u2019s disease. Cell Metab. 2022;34(3):396-407.e6.","journal-title":"Cell Metab"},{"issue":"1","key":"793_CR74","doi-asserted-by":"publisher","first-page":"7793","DOI":"10.1038\/s41467-023-43514-6","volume":"14","author":"H Berven","year":"2023","unstructured":"Berven H, Kverneng S, Sheard E, S\u00f8gnen M, Af Geijerstam SA, Haugarvoll K, et al. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson\u2019s disease. Nat Commun. 2023;14(1):7793.","journal-title":"Nat Commun"},{"key":"793_CR75","unstructured":"Joint Formulary Committee. Ursodeoxycholic acid. In: Joint Formulary Committee. British National Formulary. [BNF online]. London: BMJ Group and Pharmaceutical Press; 2025. https:\/\/bnf.nice.org.uk\/drugs\/ursodeoxycholic-acid\/. Accessed 5 Mar 2025."},{"issue":"2","key":"793_CR76","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s12035-012-8295-4","volume":"46","author":"M Castro-Caldas","year":"2012","unstructured":"Castro-Caldas M, Carvalho AN, Rodrigues E, Henderson CJ, Wolf CR, Rodrigues CMP, et al. Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson\u2019s disease. Mol Neurobiol. 2012;46(2):475\u201386.","journal-title":"Mol Neurobiol"},{"issue":"2\u20133","key":"793_CR77","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.tox.2011.11.020","volume":"292","author":"HS Chun","year":"2012","unstructured":"Chun HS, Low WC. Ursodeoxycholic acid suppresses mitochondria-dependent programmed cell death induced by sodium nitroprusside in SH-SY5Y cells. Toxicology. 2012;292(2\u20133):105\u201312.","journal-title":"Toxicology"},{"issue":"2","key":"793_CR78","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s12035-014-9043-8","volume":"53","author":"NF Abdelkader","year":"2016","unstructured":"Abdelkader NF, Safar MM, Salem HA. Ursodeoxycholic acid ameliorates apoptotic cascade in the rotenone model of Parkinson\u2019s disease: modulation of mitochondrial perturbations. Mol Neurobiol. 2016;53(2):810\u20137.","journal-title":"Mol Neurobiol"},{"key":"793_CR79","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.expneurol.2017.05.009","volume":"295","author":"S Moreira","year":"2017","unstructured":"Moreira S, Fonseca I, Nunes MJ, Rosa A, Lemos L, Rodrigues E, et al. Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson\u2019s disease. Exp Neurol. 2017;295:77\u201387.","journal-title":"Exp Neurol"},{"issue":"12","key":"793_CR80","doi-asserted-by":"publisher","first-page":"9139","DOI":"10.1007\/s12035-018-1062-4","volume":"55","author":"AI Rosa","year":"2018","unstructured":"Rosa AI, Duarte-Silva S, Silva-Fernandes A, Nunes MJ, Carvalho AN, Rodrigues E, et al. Tauroursodeoxycholic acid improves motor symptoms in a mouse model of Parkinson\u2019s disease. Mol Neurobiol. 2018;55(12):9139\u201355.","journal-title":"Mol Neurobiol"},{"key":"793_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2020.135493","volume":"741","author":"H Qi","year":"2021","unstructured":"Qi H, Shen D, Jiang C, Wang H, Chang M. Ursodeoxycholic acid protects dopaminergic neurons from oxidative stress via regulating mitochondrial function, autophagy, and apoptosis in MPTP\/MPP+-induced Parkinson\u2019s disease. Neurosci Lett. 2021;741: 135493.","journal-title":"Neurosci Lett"},{"key":"793_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2021.100348","volume":"18","author":"F Huang","year":"2021","unstructured":"Huang F. Ursodeoxycholic acid as a potential alternative therapeutic approach for neurodegenerative disorders: effects on cell apoptosis, oxidative stress and inflammation in the brain. Brain Behav Immun Health. 2021;18: 100348.","journal-title":"Brain Behav Immun Health"},{"issue":"7","key":"793_CR83","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1080\/1028415X.2020.1859729","volume":"25","author":"E Cuevas","year":"2022","unstructured":"Cuevas E, Burks S, Raymick J, Robinson B, G\u00f3mez-Cris\u00f3stomo NP, Escudero-Lourdes C, et al. Tauroursodeoxycholic acid (TUDCA) is neuroprotective in a chronic mouse model of Parkinson\u2019s disease. Nutr Neurosci. 2022;25(7):1374\u201391.","journal-title":"Nutr Neurosci"},{"issue":"10","key":"793_CR84","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1093\/brain\/awt224","volume":"136","author":"H Mortiboys","year":"2013","unstructured":"Mortiboys H, Aasly J, Bandmann O. Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson\u2019s disease. Brain. 2013;136(10):3038\u201350.","journal-title":"Brain"},{"issue":"10","key":"793_CR85","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1212\/WNL.0000000000001905","volume":"85","author":"H Mortiboys","year":"2015","unstructured":"Mortiboys H, Furmston R, Bronstad G, Aasly J, Elliott C, Bandmann O. UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2 G2019S carriers and in vivo. Neurology. 2015;85(10):846\u201352.","journal-title":"Neurology"},{"issue":"6","key":"793_CR86","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/jcph.1575","volume":"60","author":"AG Sathe","year":"2020","unstructured":"Sathe AG, Tuite P, Chen C, Ma Y, Chen W, Cloyd J, et al. Pharmacokinetics, safety, and tolerability of orally administered ursodeoxycholic acid in patients with Parkinson\u2019s disease\u2014a pilot study. J Clin Pharma. 2020;60(6):744\u201350.","journal-title":"J Clin Pharma"},{"issue":"8","key":"793_CR87","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/mds.29450","volume":"38","author":"T Payne","year":"2023","unstructured":"Payne T, Appleby M, Buckley E, Van Gelder LMA, Mullish BH, Sassani M, et al. A double-blind, randomized, placebo-controlled trial of ursodeoxycholic acid ( UDCA) in Parkinson\u2019s disease. Mov Disord. 2023;38(8):1493\u2013502.","journal-title":"Mov Disord"},{"key":"793_CR88","unstructured":"Joint Formulary Committee. Terazosin. In: Joint Formulary Committee. British National Formulary. [BNF online]. London: BMJ Group and Pharmaceutical Press; 2025. https:\/\/bnf.nice.org.uk\/drugs\/terazosin\/. Accessed 5 Mar 2025."},{"issue":"1","key":"793_CR89","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nchembio.1657","volume":"11","author":"X Chen","year":"2015","unstructured":"Chen X, Zhao C, Li X, Wang T, Li Y, Cao C, et al. Terazosin activates Pgk1 and Hsp90 to promote stress resistance. Nat Chem Biol. 2015;11(1):19\u201325.","journal-title":"Nat Chem Biol"},{"issue":"10","key":"793_CR90","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1172\/JCI129987","volume":"129","author":"R Cai","year":"2019","unstructured":"Cai R, Zhang Y, Simmering JE, Schultz JL, Li Y, Fernandez-Carasa I, et al. Enhancing glycolysis attenuates Parkinson\u2019s disease progression in models and clinical databases. J Clin Investig. 2019;129(10):4539\u201349.","journal-title":"J Clin Investig"},{"issue":"4","key":"793_CR91","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1001\/jamaneurol.2020.5157","volume":"78","author":"JE Simmering","year":"2021","unstructured":"Simmering JE, Welsh MJ, Liu L, Narayanan NS, Potteg\u00e5rd A. Association of glycolysis-enhancing \u03b1-1 blockers with risk of developing parkinson disease. JAMA Neurol. 2021;78(4):407.","journal-title":"JAMA Neurol"},{"issue":"1","key":"793_CR92","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41531-023-00477-1","volume":"9","author":"MA Weber","year":"2023","unstructured":"Weber MA, Sivakumar K, Tabakovic EE, Oya M, Aldridge GM, Zhang Q, et al. Glycolysis-enhancing \u03b11-adrenergic antagonists modify cognitive symptoms related to Parkinson\u2019s disease. npj Parkinsons Dis. 2023;9(1):32.","journal-title":"npj Parkinsons Dis."},{"issue":"2","key":"793_CR93","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.japh.2023.12.008","volume":"64","author":"KM Opheim","year":"2024","unstructured":"Opheim KM, Uc EY, Cantrell MA, Lund BC. The impact of alpha-1-adrenergic receptor antagonists on the progression of Parkinson disease. J Am Pharm Assoc. 2024;64(2):437-443.e3.","journal-title":"J Am Pharm Assoc"},{"issue":"11","key":"793_CR94","doi-asserted-by":"publisher","DOI":"10.1172\/JCI145112","volume":"131","author":"R Sasane","year":"2021","unstructured":"Sasane R, Bartels A, Field M, Sierra MI, Duvvuri S, Gray DL, et al. Parkinson disease among patients treated for benign prostatic hyperplasia with \u03b11 adrenergic receptor antagonists. J Clin Investig. 2021;131(11): e145112.","journal-title":"J Clin Investig"},{"key":"793_CR95","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.parkreldis.2021.11.022","volume":"94","author":"JL Schultz","year":"2022","unstructured":"Schultz JL, Brinker AN, Xu J, Ernst SE, Tayyari F, Rauckhorst AJ, et al. A pilot to assess target engagement of terazosin in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2022;94:79\u201383.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"793_CR96","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1124\/pharmrev.120.000133","volume":"74","author":"H Grosso Jasutkar","year":"2022","unstructured":"Grosso Jasutkar H, Oh SE, Mouradian MM. Therapeutics in the pipeline targeting \u03b1-synuclein for Parkinson\u2019s disease. Pharmacol Rev. 2022;74(1):207\u201337.","journal-title":"Pharmacol Rev"},{"issue":"5","key":"793_CR97","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2203395","volume":"387","author":"AE Lang","year":"2022","unstructured":"Lang AE, Siderowf AD, Macklin EA, Poewe W, Brooks DJ, Fernandez HH, et al. Trial of cinpanemab in early Parkinson\u2019s disease. N Engl J Med. 2022;387(5):408\u201320.","journal-title":"N Engl J Med"},{"issue":"8","key":"793_CR98","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/mds.27738","volume":"34","author":"M Brys","year":"2019","unstructured":"Brys M, Fanning L, Hung S, Ellenbogen A, Penner N, Yang M, et al. Randomized phase I clinical trial of anti\u2013\u03b1-synuclein antibody BIIB054. Mov Disord. 2019;34(8):1154\u201363.","journal-title":"Mov Disord"},{"issue":"5","key":"793_CR99","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2202867","volume":"387","author":"G Pagano","year":"2022","unstructured":"Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, et al. Trial of prasinezumab in early-stage Parkinson\u2019s disease. N Engl J Med. 2022;387(5):421\u201332.","journal-title":"N Engl J Med"},{"issue":"4","key":"793_CR100","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","volume":"30","author":"G Pagano","year":"2024","unstructured":"Pagano G, Taylor KI, Anzures Cabrera J, Simuni T, Marek K, Postuma RB, et al. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease. Nat Med. 2024;30(4):1096\u2013103.","journal-title":"Nat Med"},{"key":"793_CR101","unstructured":"AC Immune. \u2018AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson\u2019s Disease\u2019. Updated November 2024. In: https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/689a44f6-77e5-4a17-9089-b33637db3eea. Accessed Mar 2025."},{"issue":"9","key":"793_CR102","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1038\/s41591-024-03101-8","volume":"30","author":"P Eijsvogel","year":"2024","unstructured":"Eijsvogel P, Misra P, Concha-Marambio L, Boyd JD, Ding S, Fedor L, et al. Target engagement and immunogenicity of an active immunotherapeutic targeting pathological \u03b1-synuclein: a phase 1 placebo-controlled trial. Nat Med. 2024;30(9):2631\u201340.","journal-title":"Nat Med"},{"issue":"4","key":"793_CR103","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0963689718766328","volume":"27","author":"F Turcato","year":"2018","unstructured":"Turcato F, Kim P, Barnett A, Jin Y, Scerba M, Casey A, et al. Sequential combined treatment of pifithrin-\u03b1 and posiphen enhances neurogenesis and functional recovery after stroke. Cell Transplant. 2018;27(4):607\u201321.","journal-title":"Cell Transplant"},{"issue":"1","key":"793_CR104","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.trci.2017.12.001","volume":"4","author":"AF Teich","year":"2018","unstructured":"Teich AF, Sharma E, Barnwell E, Zhang H, Staniszewski A, Utsuki T, et al. Translational inhibition of APP by Posiphen: efficacy, pharmacodynamics, and pharmacokinetics in the APP\/PS1 mouse. A&D Transl Res Clin Interv. 2018;4(1):37\u201345.","journal-title":"A&D Transl Res Clin Interv"},{"issue":"1","key":"793_CR105","first-page":"1","volume":"8","author":"YM Kuo","year":"2019","unstructured":"Kuo YM, Nwankwo EI, Nussbaum RL, Rogers J, Maccecchini ML. Translational inhibition of \u03b1-synuclein by Posiphen normalizes distal colon motility in transgenic Parkinson mice. Am J Neurodegener Dis. 2019;8(1):1\u201315.","journal-title":"Am J Neurodegener Dis"},{"issue":"2","key":"793_CR106","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/alz.12185","volume":"17","author":"X Chen","year":"2021","unstructured":"Chen X, Salehi A, Pearn ML, Overk C, Nguyen PD, Kleschevnikov AM, et al. Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model. Alzheimer\u2019s Dementia. 2021;17(2):271\u201392.","journal-title":"Alzheimer\u2019s Dementia"},{"issue":"1","key":"793_CR107","doi-asserted-by":"publisher","first-page":"25","DOI":"10.14283\/jpad.2022.84","volume":"10","author":"C Fang","year":"2023","unstructured":"Fang C, Hernandez P, Liow K, Damiano E, Zetterberg H, Blennow K, et al. Buntanetap, a novel translational inhibitor of multiple neurotoxic proteins, proves to be safe and promising in both Alzheimer\u2019s and Parkinson\u2019s patients. J Prev Alzheimer\u2019s Dis. 2023;10(1):25\u201333.","journal-title":"J Prev Alzheimer\u2019s Dis"},{"key":"793_CR108","unstructured":"Annovis. Pipeline\u2014Parkinson\u2019s studies\u2014Phase 3 Study. Updated 2024. In: https:\/\/www.annovisbio.com\/pipeline#pipeline. Accessed Mar 2025."},{"key":"793_CR109","doi-asserted-by":"publisher","first-page":"113637","DOI":"10.1016\/j.biopha.2022.113637","volume":"154","author":"S Kim","year":"2022","unstructured":"Kim S, Choi JG, Kim SW, Park SC, Kang Y, Park DS, et al. Inhibition of \u03b1-synuclein aggregation by MT101-5 is neuroprotective in mouse models of Parkinson\u2019s disease. Biomed Pharmacother. 2022;154:113637.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"793_CR110","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41531-023-00552-7","volume":"9","author":"DL Price","year":"2023","unstructured":"Price DL, Khan A, Angers R, Cardenas A, Prato MK, Bani M, et al. In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson\u2019s disease. npj Parkinsons Dis. 2023;9(1):114.","journal-title":"npj Parkinsons Dis."},{"issue":"7","key":"793_CR111","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S1474-4422(20)30136-8","volume":"19","author":"D Volc","year":"2020","unstructured":"Volc D, Poewe W, Kutzelnigg A, L\u00fchrs P, Thun-Hohenstein C, Schneeberger A, et al. Safety and immunogenicity of the \u03b1-synuclein active immunotherapeutic PD01A in patients with Parkinson\u2019s disease: a randomised, single-blinded, phase 1 trial. Lancet Neurol. 2020;19(7):591\u2013600.","journal-title":"Lancet Neurol"},{"issue":"1","key":"793_CR112","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.1038\/s41467-022-32797-w","volume":"13","author":"L Antonschmidt","year":"2022","unstructured":"Antonschmidt L, Matthes D, Dervi\u015fo\u011flu R, Frieg B, Dienemann C, Leonov A, et al. The clinical drug candidate anle138b binds in a cavity of lipidic \u03b1-synuclein fibrils. Nat Commun. 2022;13(1):5385.","journal-title":"Nat Commun"},{"key":"793_CR113","doi-asserted-by":"publisher","first-page":"104021","DOI":"10.1016\/j.ebiom.2022.104021","volume":"80","author":"J Levin","year":"2022","unstructured":"Levin J, Sing N, Melbourne S, Morgan A, Mariner C, Spillantini MG, et al. Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: a randomised, double-blind, placebo-controlled phase 1a trial. EBioMedicine. 2022;80:104021.","journal-title":"EBioMedicine"},{"issue":"6","key":"793_CR114","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1021\/acschemneuro.1c00828","volume":"13","author":"BS Kim","year":"2022","unstructured":"Kim BS, Song JA, Jang KH, Jang T, Jung B, Yoo SE, et al. Pharmacological intervention targeting FAF1 restores autophagic flux for \u03b1-synuclein degradation in the brain of a Parkinson\u2019s disease mouse model. ACS Chem Neurosci. 2022;13(6):806\u201317.","journal-title":"ACS Chem Neurosci"},{"key":"793_CR115","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2147\/DDDT.S198753","volume":"13","author":"W Shin","year":"2019","unstructured":"Shin W, Lim KS, Kim MK, Kim HS, Hong J, Jhee S, et al. A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson&rsquo;s disease, in healthy volunteers. DDDT. 2019;13:1011\u201322.","journal-title":"DDDT"},{"issue":"9","key":"793_CR116","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/archneur.63.9.1225","volume":"63","author":"AHV Schapira","year":"2006","unstructured":"Schapira AHV. The importance of LRRK2 mutations in Parkinson disease. Arch Neurol. 2006;63(9):1225.","journal-title":"Arch Neurol"},{"issue":"5","key":"793_CR117","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/jnc.15524","volume":"159","author":"C Lee","year":"2021","unstructured":"Lee C, Menozzi E, Chau K, Schapira AHV. Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes. J Neurochem. 2021;159(5):826\u201339.","journal-title":"J Neurochem"},{"issue":"4","key":"793_CR118","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3233\/JPD-202138","volume":"10","author":"ML Erb","year":"2020","unstructured":"Erb ML, Moore DJ. LRRK2 and the endolysosomal system in Parkinson\u2019s disease. JPD. 2020;10(4):1271\u201391.","journal-title":"JPD"},{"key":"793_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108822","volume":"202","author":"K Senkevich","year":"2022","unstructured":"Senkevich K, Rudakou U, Gan-Or Z. New therapeutic approaches to Parkinson\u2019s disease targeting GBA, LRRK2 and Parkin. Neuropharmacology. 2022;202: 108822.","journal-title":"Neuropharmacology"},{"issue":"648","key":"793_CR120","doi-asserted-by":"publisher","first-page":"eabj2658","DOI":"10.1126\/scitranslmed.abj2658","volume":"14","author":"D Jennings","year":"2022","unstructured":"Jennings D, Huntwork-Rodriguez S, Henry AG, Sasaki JC, Meisner R, Diaz D, et al. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson\u2019s disease. Sci Transl Med. 2022;14(648):eabj2658.","journal-title":"Sci Transl Med."},{"issue":"3","key":"793_CR121","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/mds.29297","volume":"38","author":"D Jennings","year":"2023","unstructured":"Jennings D, Huntwork-Rodriguez S, Vissers MFJM, Daryani VM, Diaz D, Goo MS, et al. LRRK2 inhibition by BIIB122 in healthy participants and patients with Parkinson\u2019s disease. Mov Disord. 2023;38(3):386\u201398.","journal-title":"Mov Disord"},{"key":"793_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108419","volume":"246","author":"E Menozzi","year":"2023","unstructured":"Menozzi E, Toffoli M, Schapira AHV. Targeting the GBA1 pathway to slow Parkinson disease: insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues. Pharmacol Ther. 2023;246: 108419.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"793_CR123","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","volume":"77","author":"S Mullin","year":"2020","unstructured":"Mullin S, Smith L, Lee K, D\u2019Souza G, Woodgate P, Elflein J, et al. Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial. JAMA Neurol. 2020;77(4):427.","journal-title":"JAMA Neurol"},{"issue":"2","key":"793_CR124","doi-asserted-by":"publisher","first-page":"e000535","DOI":"10.1136\/bmjno-2023-000535","volume":"5","author":"F Colucci","year":"2023","unstructured":"Colucci F, Avenali M, De Micco R, Fusar Poli M, Cerri S, Stanziano M, et al. Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson\u2019s disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol. BMJ Neurol Open. 2023;5(2):e000535.","journal-title":"BMJ Neurol Open."},{"issue":"1","key":"793_CR125","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12883-019-1252-3","volume":"19","author":"CRA Silveira","year":"2019","unstructured":"Silveira CRA, MacKinley J, Coleman K, Li Z, Finger E, Bartha R, et al. Ambroxol as a novel disease-modifying treatment for Parkinson\u2019s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. BMC Neurol. 2019;19(1):20.","journal-title":"BMC Neurol"},{"issue":"8","key":"793_CR126","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(23)00205-3","volume":"22","author":"N Giladi","year":"2023","unstructured":"Giladi N, Alcalay RN, Cutter G, Gasser T, Gurevich T, H\u00f6glinger GU, et al. Safety and efficacy of venglustat in GBA1-associated Parkinson\u2019s disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2023;22(8):661\u201371.","journal-title":"Lancet Neurol"},{"issue":"2","key":"793_CR127","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3233\/JPD-212714","volume":"12","author":"MJ Peterschmitt","year":"2022","unstructured":"On behalf of the MOVES-PD Investigators, Peterschmitt MJ, Saiki H, Hatano T, Gasser T, Isaacson SH, et al. Safety, pharmacokinetics, and pharmacodynamics of oral venglustat in patients with Parkinson\u2019s Disease and a GBA mutation: results from part 1 of the randomized, double-blinded, placebo-controlled MOVES-PD trial. . JPD. 2022;12(2):557\u201370.","journal-title":". JPD."},{"issue":"5","key":"793_CR128","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S1734-1140(13)71480-4","volume":"65","author":"M \u015awi\u0105tkiewicz","year":"2013","unstructured":"\u015awi\u0105tkiewicz M, Zaremba M, Joniec I, Cz\u0142onkowski A, Kurkowska-Jastrz\u0119bska I. Potential neuroprotective effect of ibuprofen, insights from the mice model of Parkinson\u2019s disease. Pharmacol Rep. 2013;65(5):1227\u201336.","journal-title":"Pharmacol Rep"},{"issue":"4","key":"793_CR129","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s12640-014-9467-y","volume":"26","author":"T Zaminelli","year":"2014","unstructured":"Zaminelli T, Gradowski RW, Bassani TB, Barbiero JK, Santiago RM, Maria-Ferreira D, et al. Antidepressant and antioxidative effect of ibuprofen in the rotenone model of Parkinson\u2019s disease. Neurotox Res. 2014;26(4):351\u201362.","journal-title":"Neurotox Res"},{"issue":"10","key":"793_CR130","doi-asserted-by":"publisher","first-page":"6849","DOI":"10.1007\/s12035-015-9577-4","volume":"53","author":"A Singh","year":"2016","unstructured":"Singh A, Tripathi P, Prakash O, Singh MP. Ibuprofen abates cypermethrin-induced expression of pro-inflammatory mediators and mitogen-activated protein kinases and averts the nigrostriatal dopaminergic neurodegeneration. Mol Neurobiol. 2016;53(10):6849\u201358.","journal-title":"Mol Neurobiol"},{"issue":"3","key":"793_CR131","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1007\/s12035-017-0491-9","volume":"55","author":"P Tripathi","year":"2018","unstructured":"Tripathi P, Singh A, Bala L, Patel DK, Singh MP. Ibuprofen protects from cypermethrin-induced changes in the striatal dendritic length and spine density. Mol Neurobiol. 2018;55(3):2333\u20139.","journal-title":"Mol Neurobiol"},{"key":"793_CR132","doi-asserted-by":"publisher","DOI":"10.22038\/ijbms.2019.34011.8091","author":"E Ramazani","year":"2019","unstructured":"Ramazani E, Tayarani-Najaran Z, Fereidoni M. Celecoxib, indomethacin and ibuprofen prevent 6-hydroxydopamine-induced PC12 cell death through the inhibition of NF\u03baB and SAPK\/JNK pathways. Iran J Basic Med Sci [Internet]. 2019. https:\/\/doi.org\/10.22038\/ijbms.2019.34011.8091.","journal-title":"Iran J Basic Med Sci [Internet]"},{"issue":"2","key":"793_CR133","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s11481-020-09925-8","volume":"16","author":"T Costa","year":"2021","unstructured":"Costa T, Fernandez-Villalba E, Izura V, Lucas-Ochoa A, Menezes-Filho N, Santana R, et al. Combined 1-deoxynojirimycin and ibuprofen treatment decreases microglial activation, phagocytosis and dopaminergic degeneration in MPTP-treated mice. J Neuroimmune Pharmacol. 2021;16(2):390\u2013402.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"6","key":"793_CR134","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/ana.20682","volume":"58","author":"H Chen","year":"2005","unstructured":"Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson\u2019s disease. Ann Neurol. 2005;58(6):963\u20137.","journal-title":"Ann Neurol"},{"issue":"12","key":"793_CR135","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1212\/WNL.0b013e3181d5a4a3","volume":"74","author":"JJ Gagne","year":"2010","unstructured":"Gagne JJ, Power MC. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology. 2010;74(12):995\u20131002.","journal-title":"Neurology"},{"issue":"10","key":"793_CR136","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1212\/WNL.0b013e31820f2d79","volume":"76","author":"X Gao","year":"2011","unstructured":"Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology. 2011;76(10):863\u20139.","journal-title":"Neurology"},{"issue":"37","key":"793_CR137","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012172","volume":"97","author":"L Ren","year":"2018","unstructured":"Ren L, Yi J, Yang J, Li P, Cheng X, Mao P. Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease: a dose\u2013response meta-analysis. Medicine. 2018;97(37): e12172.","journal-title":"Medicine"},{"issue":"8","key":"793_CR138","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1001\/archneur.60.8.1059","volume":"60","author":"H Chen","year":"2003","unstructured":"Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol. 2003;60(8):1059\u201364.","journal-title":"Arch Neurol."},{"issue":"10","key":"793_CR139","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/mds.28189","volume":"35","author":"M San Luciano","year":"2020","unstructured":"San Luciano M, Tanner CM, Meng C, Marras C, Goldman SM, Lang AE, et al. Nonsteroidal anti-inflammatory use and LRRK2 Parkinson\u2019s disease penetrance. Mov Disord. 2020;35(10):1755\u201364.","journal-title":"Mov Disord"},{"issue":"1","key":"793_CR140","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00228-018-2561-y","volume":"75","author":"TN Poly","year":"2019","unstructured":"Poly TN, Islam MDM, Yang HC, Li YCJ. Non-steroidal anti-inflammatory drugs and risk of Parkinson\u2019s disease in the elderly population: a meta-analysis. Eur J Clin Pharmacol. 2019;75(1):99\u2013108.","journal-title":"Eur J Clin Pharmacol"},{"key":"793_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.120822","volume":"454","author":"G Kuhlman","year":"2023","unstructured":"Kuhlman G, Auinger P, Duff-Canning S, Lang A, Tanner C, Marras C. Non-steroidal anti-inflammatory drug use and markers of Parkinson\u2019s disease progression: a retrospective cohort study. J Neurol Sci. 2023;454: 120822.","journal-title":"J Neurol Sci"},{"issue":"4","key":"793_CR142","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3233\/JPD-171203","volume":"7","author":"CB Carroll","year":"2017","unstructured":"Carroll CB, Wyse RKH. Simvastatin as a potential disease-modifying therapy for patients with Parkinson\u2019s disease: rationale for clinical trial, and current progress. J Parkinson\u2019s Dis. 2017;7(4):545\u201368.","journal-title":"J Parkinson\u2019s Dis"},{"issue":"2","key":"793_CR143","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1063","volume":"11","author":"HM Al-kuraishy","year":"2023","unstructured":"Al-kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Alsayegh AA, Almohmadi NH, et al. Pros and cons for statins use and risk of Parkinson\u2019s disease: an updated perspective. Pharmacol Res Perspect. 2023;11(2): e01063.","journal-title":"Pharmacol Res Perspect"},{"issue":"5","key":"793_CR144","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1002\/mds.28474","volume":"36","author":"C Lin","year":"2021","unstructured":"Lin C, Chang C, Tai C, Cheng M, Chen Y, Chao Y, et al. A double-blind, randomized, controlled trial of lovastatin in early-stage Parkinson\u2019s disease. Mov Disord. 2021;36(5):1229\u201337.","journal-title":"Mov Disord"},{"issue":"12","key":"793_CR145","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1001\/jamaneurol.2022.3718","volume":"79","author":"KN Stevens","year":"2022","unstructured":"Stevens KN, Creanor S, Jeffery A, Whone A, Zajicek J, Foggo A, et al. Evaluation of simvastatin as a disease-modifying treatment for patients with Parkinson disease: a randomized clinical trial. JAMA Neurol. 2022;79(12):1232.","journal-title":"JAMA Neurol"},{"issue":"4","key":"793_CR146","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/BF02220605","volume":"43","author":"L Lennard","year":"1992","unstructured":"Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43(4):329\u201339.","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"793_CR147","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1172\/JCI16432","volume":"111","author":"I Tiede","year":"2003","unstructured":"Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Investig. 2003;111(8):1133\u201345.","journal-title":"J Clin Investig"},{"issue":"11","key":"793_CR148","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-040527","volume":"10","author":"JC Greenland","year":"2020","unstructured":"Greenland JC, Cutting E, Kadyan S, Bond S, Chhabra A, Williams-Gray CH. Azathioprine immunosuppression and disease modification in Parkinson\u2019s disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial protocol. BMJ Open. 2020;10(11): e040527.","journal-title":"BMJ Open"},{"issue":"1","key":"793_CR149","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.nbd.2011.02.011","volume":"43","author":"EN Mangano","year":"2011","unstructured":"Mangano EN, Peters S, Litteljohn D, So R, Bethune C, Bobyn J, et al. Granulocyte macrophage-colony stimulating factor protects against substantia nigra dopaminergic cell loss in an environmental toxin model of Parkinson\u2019s disease. Neurobiol Dis. 2011;43(1):99\u2013112.","journal-title":"Neurobiol Dis"},{"issue":"1\u20132","key":"793_CR150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2013.10.009","volume":"265","author":"LM Kosloski","year":"2013","unstructured":"Kosloski LM, Kosmacek EA, Olson KE, Mosley RL, Gendelman HE. GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice. J Neuroimmunol. 2013;265(1\u20132):1\u201310.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"793_CR151","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41531-017-0013-5","volume":"3","author":"HE Gendelman","year":"2017","unstructured":"Gendelman HE, Zhang Y, Santamaria P, Olson KE, Schutt CR, Bhatti D, et al. Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson\u2019s disease trial. npj Parkinson\u2019s Dis. 2017;3(1):10.","journal-title":"npj Parkinson\u2019s Dis."},{"issue":"1","key":"793_CR152","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40035-023-00361-1","volume":"12","author":"KE Olson","year":"2023","unstructured":"Olson KE, Abdelmoaty MM, Namminga KL, Lu Y, Obaro H, Santamaria P, et al. An open-label multiyear study of sargramostim-treated Parkinson\u2019s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers. Transl Neurodegener. 2023;12(1):26.","journal-title":"Transl Neurodegener"},{"issue":"3","key":"793_CR153","first-page":"199","volume":"1","author":"AD Bachstetter","year":"2010","unstructured":"Bachstetter AD, Eldik LJV. The p38 MAP kinase family as regulators of proinflammatory cytokine production in degenerative diseases of the CNS. Aging Dis. 2010;1(3):199\u2013211.","journal-title":"Aging Dis."},{"issue":"1","key":"793_CR154","doi-asserted-by":"publisher","first-page":"5308","DOI":"10.1038\/s41467-022-32944-3","volume":"13","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Alam JJ, Gomperts SN, Maruff P, Lemstra AW, Germann UA, et al. Preclinical and randomized clinical evaluation of the p38\u03b1 kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration. Nat Commun. 2022;13(1):5308.","journal-title":"Nat Commun"},{"issue":"1","key":"793_CR155","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13195-021-00843-2","volume":"13","author":"ND Prins","year":"2021","unstructured":"For the REVERSE-SD Study Investigators, Prins ND, Harrison JE, Chu HM, Blackburn K, Alam JJ, et al. A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther. 2021;13(1):106.","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"793_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.105134","volume":"146","author":"KB Wilkins","year":"2020","unstructured":"Wilkins KB, Parker JE, Bronte-Stewart HM. Gait variability is linked to the atrophy of the Nucleus Basalis of Meynert and is resistant to STN DBS in Parkinson\u2019s disease. Neurobiol Dis. 2020;146: 105134.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"793_CR157","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/mds.28453","volume":"36","author":"J Wilson","year":"2021","unstructured":"Wilson J, Yarnall AJ, Craig CE, Galna B, Lord S, Morris R, et al. Cholinergic basal forebrain volumes predict gait decline in Parkinson\u2019s disease. Mov Disord. 2021;36(3):611\u201321.","journal-title":"Mov Disord"},{"issue":"17","key":"793_CR158","doi-asserted-by":"publisher","first-page":"7565","DOI":"10.1007\/s00253-018-9155-6","volume":"102","author":"T Chen","year":"2018","unstructured":"Chen T, Tian P, Huang Z, Zhao X, Wang H, Xia C, et al. Engineered commensal bacteria prevent systemic inflammation-induced memory impairment and amyloidogenesis via producing GLP-1. Appl Microbiol Biotechnol. 2018;102(17):7565\u201375.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"1","key":"793_CR159","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/JPD-181503","volume":"9","author":"L Zhang","year":"2019","unstructured":"Zhang L, Zhang L, Li L, H\u00f6lscher C. Semaglutide is neuroprotective and reduces \u03b1-synuclein levels in the chronic MPTP mouse model of Parkinson\u2019s disease. JPD. 2019;9(1):157\u201371.","journal-title":"JPD"},{"key":"793_CR160","doi-asserted-by":"crossref","unstructured":"Nassar M, Gill AS, Marte E. Investigating the impact of intestinal glucagon-like peptide-1 on hypoglycemia in type 1 diabetes. World J Diabetes [Internet]. 2025;16(3). https:\/\/www.wjgnet.com\/1948-9358\/full\/v16\/i3\/99142.htm. Accessed 11 Apr 2025.","DOI":"10.4239\/wjd.v16.i3.99142"},{"issue":"6","key":"793_CR161","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1172\/JCI68295","volume":"123","author":"I Aviles-Olmos","year":"2013","unstructured":"Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, et al. Exenatide and the treatment of patients with Parkinson\u2019s disease. J Clin Investig. 2013;123(6):2730\u20136.","journal-title":"J Clin Investig"},{"issue":"3","key":"793_CR162","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3233\/JPD-140364","volume":"4","author":"I Aviles-Olmos","year":"2014","unstructured":"Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Ell P, et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson\u2019s disease. JPD. 2014;4(3):337\u201344.","journal-title":"JPD"},{"issue":"10103","key":"793_CR163","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, et al. Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664\u201375.","journal-title":"Lancet"},{"issue":"4","key":"793_CR164","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamaneurol.2018.4304","volume":"76","author":"D Athauda","year":"2019","unstructured":"Athauda D, Gulyani S, Karnati HK, Li Y, Tweedie D, Mustapic M, et al. Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease: a secondary analysis of the exenatide-PD trial. JAMA Neurol. 2019;76(4):420.","journal-title":"JAMA Neurol"},{"issue":"5","key":"793_CR165","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-047993","volume":"11","author":"N Vijiaratnam","year":"2021","unstructured":"Vijiaratnam N, Girges C, Auld G, Chau M, Maclagan K, King A, et al. Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson\u2019s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The \u2018Exenatide-PD3\u2019 study. BMJ Open. 2021;11(5): e047993.","journal-title":"BMJ Open"},{"issue":"10479","key":"793_CR166","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","volume":"405","author":"N Vijiaratnam","year":"2025","unstructured":"Vijiaratnam N, Girges C, Auld G, McComish R, King A, Skene SS, et al. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet. 2025;405(10479):627\u201336.","journal-title":"Lancet"},{"issue":"1","key":"793_CR167","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","volume":"23","author":"A McGarry","year":"2024","unstructured":"McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, et al. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2024;23(1):37\u201345.","journal-title":"Lancet Neurol"},{"issue":"13","key":"793_CR168","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner WG, Remy P, Giordana C, Malt\u00eate D, Derkinderen P, Hou\u00e9to JL, et al. Trial of lixisenatide in early Parkinson\u2019s disease. N Engl J Med. 2024;390(13):1176\u201385.","journal-title":"N Engl J Med"},{"issue":"18 Supplement","key":"793_CR169","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1212\/WNL.98.18_supplement.3068","volume":"98","author":"C Malatt","year":"2022","unstructured":"Malatt C, Wu T, Bresee C, Hogg E, Wetheimer J, Tan E, et al. Liraglutide improves non-motor function and activities of daily living in patients with Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled trial (P9-11.005). Neurology. 2022;98(18 Supplement):3068.","journal-title":"Neurology"},{"key":"793_CR170","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1016\/j.parkreldis.2008.04.012","volume":"14","author":"GE Meredith","year":"2008","unstructured":"Meredith GE, Totterdell S, Potashkin JA, Surmeier DJ. Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat Disord. 2008;14:S112\u20135.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"793_CR171","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.nbd.2011.04.007","volume":"43","author":"E Ilijic","year":"2011","unstructured":"Ilijic E, Guzman JN, Surmeier DJ. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson\u2019s disease. Neurobiol Dis. 2011;43(2):364\u201371.","journal-title":"Neurobiol Dis"},{"issue":"12","key":"793_CR172","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1016\/j.cellsig.2013.09.004","volume":"25","author":"T Chen","year":"2013","unstructured":"Chen T, Yang Y, Luo P, Liu W, Dai S, Zheng X, et al. Homer1 knockdown protects dopamine neurons through regulating calcium homeostasis in an in vitro model of Parkinson\u2019s disease. Cell Signal. 2013;25(12):2863\u201370.","journal-title":"Cell Signal"},{"issue":"3","key":"793_CR173","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1152\/jn.00432.2014","volume":"114","author":"G Cooper","year":"2015","unstructured":"Cooper G, Lasser-Katz E, Simchovitz A, Sharon R, Soreq H, Surmeier DJ, et al. Functional segregation of voltage-activated calcium channels in motoneurons of the dorsal motor nucleus of the vagus. J Neurophysiol. 2015;114(3):1513\u201320.","journal-title":"J Neurophysiol"},{"key":"793_CR174","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2017.05.012","volume":"1670","author":"YL Wang","year":"2017","unstructured":"Wang YL, Wang JG, Guo FL, Gao XH, Zhao DD, Zhang L, et al. Selective dopamine receptor 4 activation mediates the hippocampal neuronal calcium response via IP3 and ryanodine receptors. Brain Res. 2017;1670:1\u20135.","journal-title":"Brain Res"},{"issue":"6","key":"793_CR175","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1172\/JCI95898","volume":"128","author":"JN Guzman","year":"2018","unstructured":"Guzman JN, Ilijic E, Yang B, Sanchez-Padilla J, Wokosin D, Galtieri D, et al. Systemic isradipine treatment diminishes calcium-dependent mitochondrial oxidant stress. J Clin Investig. 2018;128(6):2266\u201380.","journal-title":"J Clin Investig"},{"issue":"23","key":"793_CR176","doi-asserted-by":"publisher","first-page":"eabm4560","DOI":"10.1126\/sciadv.abm4560","volume":"8","author":"J Shin","year":"2022","unstructured":"Shin J, Kovacheva L, Thomas D, Stojanovic S, Knowlton CJ, Mankel J, et al. Cav1.3 calcium channels are full-range linear amplifiers of firing frequencies in lateral DA SN neurons. Sci Adv. 2022;8(23):eabm4560.","journal-title":"Sci Adv"},{"key":"793_CR177","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.neuroscience.2014.10.037","volume":"284","author":"E Dragicevic","year":"2015","unstructured":"Dragicevic E, Schiemann J, Liss B. Dopamine midbrain neurons in health and Parkinson\u2019s disease: emerging roles of voltage-gated calcium channels and ATP-sensitive potassium channels. Neuroscience. 2015;284:798\u2013814.","journal-title":"Neuroscience"},{"key":"793_CR178","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1212\/01.wnl.0000303818.38960.44","volume":"70","author":"C Becker","year":"2008","unstructured":"Becker C, Jick SS, Meier CR. Use of antihypertensives and the risk of Parkinson disease. Neurology. 2008;70:1438\u201344.","journal-title":"Neurology"},{"issue":"5","key":"793_CR179","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/ana.21937","volume":"67","author":"B Ritz","year":"2010","unstructured":"Ritz B, Rhodes SL, Qian L, Schernhammer E, Olsen JH, Friis S. L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol. 2010;67(5):600\u20136.","journal-title":"Ann Neurol"},{"issue":"11","key":"793_CR180","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s40261-019-00830-4","volume":"39","author":"MS Cepeda","year":"2019","unstructured":"Cepeda MS, Kern DM, Seabrook GR, Lovestone S. Comprehensive real-world assessment of marketed medications to guide Parkinson\u2019s drug discovery. Clin Drug Investig. 2019;39(11):1067\u201375.","journal-title":"Clin Drug Investig"},{"key":"793_CR181","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/S0024-3205(97)00881-3","volume":"61","author":"S Uchida","year":"1997","unstructured":"Uchida S, Yamada S, Nagai K, et al. Brain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyridine calcium channel antagonists. Life Sci. 1997;61:2083\u201390.","journal-title":"Life Sci"},{"key":"793_CR182","volume-title":"Drug class review: calcium channel blockers: final report [Internet]","author":"MS McDonagh","year":"2005","unstructured":"McDonagh MS, Eden KB, Peterson K. Drug class review: calcium channel blockers: final report [Internet]. Portland: Oregon Health and Science University; 2005."},{"issue":"9","key":"793_CR183","doi-asserted-by":"publisher","first-page":"591","DOI":"10.7326\/M19-2534","volume":"172","author":"The Parkinson Study Group STEADY-PD III Investigators","year":"2020","unstructured":"The Parkinson Study Group STEADY-PD III Investigators. Isradipine versus placebo in early Parkinson disease: a randomized trial. Ann Intern Med. 2020;172(9):591\u20138.","journal-title":"Ann Intern Med"},{"issue":"2","key":"793_CR184","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/mds.28850","volume":"37","author":"DJ Surmeier","year":"2022","unstructured":"Surmeier DJ, Nguyen JT, Lancki N, Venuto CS, Oakes D, Simuni T, et al. Re-analysis of the STEADY-PD II trial\u2014evidence for slowing the progression of Parkinson\u2019s disease. Mov Disord. 2022;37(2):334\u201342.","journal-title":"Mov Disord"},{"issue":"1","key":"793_CR185","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1212\/01.wnl.0000250236.75053.16","volume":"68","author":"M Murata","year":"2007","unstructured":"Murata M, Hasegawa K, Kanazawa I, The Japan Zonisamide on PD Study Group. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology. 2007;68(1):45\u201350.","journal-title":"Neurology"},{"issue":"10","key":"793_CR186","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/mds.26286","volume":"30","author":"M Murata","year":"2015","unstructured":"Murata M, Hasegawa K, Kanazawa I, Fukasaka J, Kochi K, Shimazu R, et al. Zonisamide improves wearing-off in Parkinson\u2019s disease: a randomized, double-blind study. Mov Disord. 2015;30(10):1343\u201350.","journal-title":"Mov Disord"},{"key":"793_CR187","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.parkreldis.2019.12.005","volume":"76","author":"M Murata","year":"2020","unstructured":"Murata M, Odawara T, Hasegawa K, Kajiwara R, Takeuchi H, Tagawa M, et al. Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: a phase 3 randomized clinical trial. Parkinsonism Relat Disord. 2020;76:91\u20137.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"793_CR188","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/ana.21885","volume":"67","author":"M Asanuma","year":"2010","unstructured":"Asanuma M, Miyazaki I, Diaz-Corrales FJ, Kimoto N, Kikkawa Y, Takeshima M, et al. Neuroprotective effects of zonisamide target astrocyte. Ann Neurol. 2010;67(2):239\u201349.","journal-title":"Ann Neurol"},{"issue":"2","key":"793_CR189","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.expneurol.2009.11.018","volume":"221","author":"PK Sonsalla","year":"2010","unstructured":"Sonsalla PK, Wong LY, Winnik B, Buckley B. The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010;221(2):329\u201334.","journal-title":"Exp Neurol"},{"issue":"2","key":"793_CR190","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10571-012-9886-3","volume":"33","author":"VA Y\u00fcrekli","year":"2013","unstructured":"Y\u00fcrekli VA, G\u00fcrler S, Naz\u0131ro\u011flu M, U\u011fuz AC, Koyuncuo\u011flu HR. Zonisamide attenuates MPP(+)-induced oxidative toxicity through modulation of Ca2+ signaling and caspase-3 activity in neuronal PC12 cells. Cell Mol Neurobiol. 2013;33(2):205\u201312.","journal-title":"Cell Mol Neurobiol"},{"issue":"4","key":"793_CR191","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00424-014-1466-6","volume":"466","author":"YC Yang","year":"2014","unstructured":"Yang YC, Tai CH, Pan MK, Kuo CC. The T-type calcium channel as a new therapeutic target for Parkinson\u2019s disease. Pflugers Arch Eur J Physiol. 2014;466(4):747\u201355.","journal-title":"Pflugers Arch Eur J Physiol"},{"key":"793_CR192","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ejphar.2014.09.023","volume":"746","author":"S Tsujii","year":"2015","unstructured":"Tsujii S, Ishisaka M, Shimazawa M, Hashizume T, Hara H. Zonisamide suppresses endoplasmic reticulum stress-induced neuronal cell damage in vitro and in vivo. Eur J Pharmacol. 2015;746:301\u20137.","journal-title":"Eur J Pharmacol"},{"key":"793_CR193","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.expneurol.2018.07.005","volume":"308","author":"MM Hossain","year":"2018","unstructured":"Hossain MM, Weig B, Reuhl K, Gearing M, Wu LJ, Richardson JR. The anti-parkinsonian drug zonisamide reduces neuroinflammation: role of microglial Nav 1.6. Exp Neurol. 2018;308:111\u20139.","journal-title":"Exp Neurol"},{"key":"793_CR194","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jns.2018.05.013","volume":"391","author":"K Ikeda","year":"2018","unstructured":"Ikeda K, Yanagihashi M, Miura K, Ishikawa Y, Hirayama T, Takazawa T, et al. Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: a retrospective, observational cohort study. J Neurol Sci. 2018;391:5\u20139.","journal-title":"J Neurol Sci"},{"key":"793_CR195","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jns.2019.05.028","volume":"402","author":"H Iwaki","year":"2019","unstructured":"Iwaki H, Tagawa M, Iwasaki K, Kawakami K, Nomoto M. Comparison of zonisamide with non-levodopa, anti-Parkinson\u2019s disease drugs in the incidence of Parkinson\u2019s disease-relevant symptoms. J Neurol Sci. 2019;402:145\u201352.","journal-title":"J Neurol Sci"},{"issue":"1","key":"793_CR196","doi-asserted-by":"publisher","first-page":"4708","DOI":"10.1038\/s41598-024-55233-z","volume":"14","author":"T Terada","year":"2024","unstructured":"Terada T, Bunai T, Hashizume T, Matsudaira T, Yokokura M, Takashima H, et al. Neuroinflammation following anti-parkinsonian drugs in early Parkinson\u2019s disease: a longitudinal PET study. Sci Rep. 2024;14(1):4708.","journal-title":"Sci Rep"},{"issue":"2","key":"793_CR197","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1527-3458.2005.tb00269.x","volume":"11","author":"F Blandini","year":"2005","unstructured":"Blandini F. Neuroprotection by rasagiline: a new therapeutic approach to Parkinson\u2019s disease? CNS Drug Rev. 2005;11(2):183\u201394.","journal-title":"CNS Drug Rev."},{"issue":"5","key":"793_CR198","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2174\/156720506779025288","volume":"3","author":"M Youdim","year":"2006","unstructured":"Youdim M. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and M30. CAR. 2006;3(5):541\u201350.","journal-title":"CAR"},{"issue":"10","key":"793_CR199","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1007\/s11064-007-9351-8","volume":"32","author":"SA Mandel","year":"2007","unstructured":"Mandel SA, Sagi Y, Amit T. Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway. Neurochem Res. 2007;32(10):1694\u20139.","journal-title":"Neurochem Res"},{"issue":"11","key":"793_CR200","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s00702-009-0225-x","volume":"116","author":"O Weinreb","year":"2009","unstructured":"Weinreb O, Amit T, Sagi Y, Drigues N, Youdim MBH. Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson\u2019s disease drug, rasagiline compared with selegiline, in the rat midbrain. J Neural Transm. 2009;116(11):1457\u201372.","journal-title":"J Neural Transm"},{"issue":"3","key":"793_CR201","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.pneurobio.2010.06.008","volume":"92","author":"O Weinreb","year":"2010","unstructured":"Weinreb O, Amit T, Bar-Am O, Youdim MBH. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol. 2010;92(3):330\u201344.","journal-title":"Prog Neurobiol"},{"issue":"13","key":"793_CR202","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","volume":"361","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease. N Engl J Med. 2009;361(13):1268\u201378.","journal-title":"N Engl J Med"},{"issue":"10","key":"793_CR203","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1002\/mds.26724","volume":"31","author":"O Rascol","year":"2016","unstructured":"Rascol O, Hauser RA, Stocchi F, Fitzer-Attas CJ, Sidi Y, Abler V, et al. Long-term effects of rasagiline and the natural history of treated Parkinson\u2019s disease. Mov Disord. 2016;31(10):1489\u201396.","journal-title":"Mov Disord"},{"issue":"1","key":"793_CR204","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11481-018-09831-0","volume":"15","author":"L Magistrelli","year":"2020","unstructured":"Magistrelli L, Comi C. Beta2-adrenoceptor agonists in Parkinson\u2019s disease and other synucleinopathies. J Neuroimmune Pharmacol. 2020;15(1):74\u201381.","journal-title":"J Neuroimmune Pharmacol"},{"key":"793_CR205","unstructured":"Joint Formulary Committee. Salbutamol. In: Joint Formulary Committee. British National Formulary [BNF online][]. London: BMJ Group and Pharmaceutical Press; 2025. https:\/\/bnf.nice.org.uk\/drugs\/salbutamol\/. Accessed Jan 2025."},{"issue":"6354","key":"793_CR206","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1126\/science.aaf3934","volume":"357","author":"S Mittal","year":"2017","unstructured":"Mittal S, Bj\u00f8rnevik K, Im DS, Flierl A, Dong X, Locascio JJ, et al. \u03b22-Adrenoreceptor is a regulator of the \u03b1-synuclein gene driving risk of Parkinson\u2019s disease. Science. 2017;357(6354):891\u20138.","journal-title":"Science"},{"issue":"5","key":"793_CR207","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/ana.25341","volume":"84","author":"S Searles Nielsen","year":"2018","unstructured":"Searles Nielsen S, Gross A, Camacho-Soto A, Willis AW, Racette BA. \u03b22-Adrenoreceptor medications and risk of Parkinson disease. Ann Neurol. 2018;84(5):683\u201393.","journal-title":"Ann Neurol"},{"issue":"8797","key":"793_CR208","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/0140-6736(92)90313-R","volume":"339","author":"R Hishida","year":"1992","unstructured":"Hishida R, Kurahashi K, Shoko N, Baba T, Muneo M. \u2018Wearing-off\u2019 and beta 2-adrenoceptor agonist in Parkinson\u2019s disease. Lancet. 1992;339(8797):870.","journal-title":"Lancet"},{"issue":"8","key":"793_CR209","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1212\/WNL.44.8.1511","volume":"44","author":"GM Alexander","year":"1994","unstructured":"Alexander GM, Schwartzman RJ, Nukes TA, Grothusen JR, Hooker MD. \u03b22-Adrenergic agonist as adjunct therapy to levodopa in Parkinson\u2019s disease. Neurology. 1994;44(8):1511\u20131511.","journal-title":"Neurology"},{"issue":"4","key":"793_CR210","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/00002826-200307000-00011","volume":"26","author":"EY Uc","year":"2003","unstructured":"Uc EY, Lambert CP, Harik SI, Rodnitzky RL, Evans WJ. Albuterol improves response to levodopa and increases skeletal muscle mass in patients with fluctuating Parkinson disease. Clin Neuropharmacol. 2003;26(4):207\u201312.","journal-title":"Clin Neuropharmacol"},{"key":"793_CR211","unstructured":"Australian New Zealand Clinical Trials Registry. https:\/\/www.64anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=375958&65isReview=true. Accessed 13 Apr 2025."},{"issue":"2","key":"793_CR212","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00702-019-02138-1","volume":"127","author":"D Devos","year":"2020","unstructured":"The FAIRPARK-II and FAIRALS-II Studygroups, Devos D, Cabantchik ZI, Moreau C, Danel V, Mahoney-Sanchez L, et al. Conservative iron chelation for neurodegenerative diseases such as Parkinson\u2019s disease and amyotrophic lateral sclerosis. J Neural Transm. 2020;127(2):189\u2013203.","journal-title":"J Neural Transm"},{"key":"793_CR213","unstructured":"Joint Formulary Committee. Deferiprone. In: Joint Formulary Committee. British National Formulary [BNF online]. London: BMJ Group and Pharmaceutical Press; 2025. https:\/\/bnf.nice.org.uk\/drugs\/deferiprone\/. Accessed Jan 2025."},{"issue":"2","key":"793_CR214","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1089\/ars.2013.5593","volume":"21","author":"D Devos","year":"2014","unstructured":"Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, et al. Targeting chelatable iron as a therapeutic modality in Parkinson\u2019s disease. Antioxid Redox Signal. 2014;21(2):195\u2013210.","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"793_CR215","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41598-017-01402-2","volume":"7","author":"A Martin-Bastida","year":"2017","unstructured":"Martin-Bastida A, Ward RJ, Newbould R, Piccini P, Sharp D, Kabba C, et al. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson\u2019s disease. Sci Rep. 2017;7(1):1398.","journal-title":"Sci Rep"},{"issue":"22","key":"793_CR216","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1056\/NEJMoa2209254","volume":"387","author":"D Devos","year":"2022","unstructured":"Devos D, Labreuche J, Rascol O, Corvol JC, Duhamel A, Guyon Delannoy P, et al. Trial of deferiprone in Parkinson\u2019s disease. N Engl J Med. 2022;387(22):2045\u201355.","journal-title":"N Engl J Med"},{"issue":"1","key":"793_CR217","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3233\/JPD-160912","volume":"7","author":"MR Rafferty","year":"2016","unstructured":"Rafferty MR, Schmidt PN, Luo ST, Li K, Marras C, Davis TL, et al. Regular exercise, quality of life, and mobility in Parkinson\u2019s disease: a longitudinal analysis of National Parkinson Foundation Quality Improvement Initiative Data. J Parkinson\u2019s Dis. 2016;7(1):193\u2013202.","journal-title":"J Parkinson\u2019s Dis"},{"issue":"1","key":"793_CR218","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/NPT.0000000000000163","volume":"41","author":"MR Rafferty","year":"2017","unstructured":"Rafferty MR, Prodoehl J, Robichaud JA, David FJ, Poon C, Goelz LC, et al. Effects of 2 years of exercise on gait impairment in people with Parkinson disease: the PRET-PD randomized trial. J Neurol Phys Ther. 2017;41(1):21\u201330.","journal-title":"J Neurol Phys Ther"},{"key":"793_CR219","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000013218","author":"K Tsukita","year":"2022","unstructured":"Tsukita K, Sakamaki-Tsukita H, Takahashi R. Long-term effect of regular physical activity and exercise habits in patients with early Parkinson disease. Neurology [Internet]. 2022. https:\/\/doi.org\/10.1212\/WNL.0000000000013218.","journal-title":"Neurology [Internet]"},{"issue":"12","key":"793_CR220","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1001\/jamaneurol.2021.3926","volume":"78","author":"SY Yoon","year":"2021","unstructured":"Yoon SY, Suh JH, Yang SN, Han K, Kim YW. Association of physical activity, including amount and maintenance, with all-cause mortality in Parkinson disease. JAMA Neurol. 2021;78(12):1446.","journal-title":"JAMA Neurol"},{"issue":"11","key":"793_CR221","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrneurol.2017.128","volume":"13","author":"MK Mak","year":"2017","unstructured":"Mak MK, Wong-Yu IS, Shen X, Chung CL. Long-term effects of exercise and physical therapy in people with Parkinson disease. Nat Rev Neurol. 2017;13(11):689\u2013703.","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"793_CR222","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S1474-4422(19)30285-6","volume":"18","author":"NM Van Der Kolk","year":"2019","unstructured":"Van Der Kolk NM, De Vries NM, Kessels RPC, Joosten H, Zwinderman AH, Post B, et al. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson\u2019s disease: a double-blind, randomised controlled trial. Lancet Neurol. 2019;18(11):998\u20131008.","journal-title":"Lancet Neurol"},{"issue":"1","key":"793_CR223","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s12883-023-03355-8","volume":"23","author":"S Schootemeijer","year":"2023","unstructured":"Schootemeijer S, De Vries NM, Macklin EA, Roes KCB, Joosten H, Omberg L, et al. The STEPWISE study: study protocol for a smartphone-based exercise solution for people with Parkinson\u2019s disease (randomized controlled trial). BMC Neurol. 2023;23(1):323.","journal-title":"BMC Neurol"},{"issue":"2","key":"793_CR224","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/NPT.0000000000000507","volume":"49","author":"S Schootemeijer","year":"2025","unstructured":"Schootemeijer S, De Vries NM, Darweesh SKL, Ascherio A, Schwarzschild MA, Macklin EA, et al. Promoting physical activity in people with Parkinson\u2019s disease through a smartphone app: a pilot study. J Neurol Phys Ther. 2025;49(2):74\u201381.","journal-title":"J Neurol Phys Ther"},{"issue":"8","key":"793_CR225","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.3233\/JPD-229006","volume":"12","author":"S Schootemeijer","year":"2022","unstructured":"Schootemeijer S, Darweesh SKL, De Vries NM. Clinical trial highlights\u2014aerobic exercise for Parkinson\u2019s disease. JPD. 2022;12(8):2297\u2013306.","journal-title":"JPD."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00793-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00793-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00793-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T12:03:22Z","timestamp":1758369802000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00793-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":225,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["793"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00793-z","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Cristina Gonzalez-Robles has received research support from the Edmond J. Safra (EJS) Foundation (EJS Accelerating Clinical Trials in Parkinson\u2019s Disease (EJS ACT-PD) project). Oliver Bandmann has received grants from Cure Parkinson\u2019s (OB02), the Medical Research Council (MRC)\u2014Centre of Excellence Award (CoEN) (MR\/V006525\/1) and the Jon Moulton Charity Trust. He has served on the Advisory Board for ICE. Anthony HV Schapira has received grants from the MRC (UK), Cure Parkinson\u2019s Trust, Parkinson\u2019s UK, EU H2020 program and Aligning Science Against Parkinson\u2019s (ASAP), MJFF, Innovate UK and consults for Capsida and Neurocrine. Anthony HV Schapira is an Editorial Board member of Neurology and Therapy. Anthony HV Schapira was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}